Telesis Bio Price to Free Cash Flow Ratio 2021-2024 | TBIO

Telesis Bio price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as

Telesis Bio Price to Free Cash Flow Ratio 2021-2024 | TBIO

Telesis Bio price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.5B
Vertex Pharmaceuticals (VRTX)$121.6B
Gilead Sciences (GILD)$111.4B
Bristol Myers Squibb (BMY)$110.1B
Regeneron Pharmaceuticals (REGN)$93B
CSL (CSLLY)$90B
GSK (GSK)$76.4B
Argenex SE (ARGX)$35.6B
Alnylam Pharmaceuticals (ALNY)$35.2B
BioNTech SE (BNTX)$26.5B
Biogen (BIIB)$25.3B
Illumina (ILMN)$23.9B
Moderna (MRNA)$21B
BeiGene (BGNE)$19.9B
Genmab (GMAB)$14.9B
Incyte (INCY)$14.7B
Exact Sciences (EXAS)$12.9B
BioMarin Pharmaceutical (BMRN)$12.6B
Vaxcyte (PCVX)$12B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.8B
Insmed (INSM)$11.7B
QIAGEN (QGEN)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.3B
Revolution Medicines (RVMD)$9.2B
Intra-Cellular Therapies (ITCI)$9.2B
Roivant Sciences (ROIV)$8.6B
Viking Therapeutics (VKTX)$8.1B
Legend Biotech (LEGN)$8.1B